See the DrugPatentWatch profile for lurbinectedin
Based on the information provided, there is no specific patient population that should avoid lurbinectedin. However, it is essential to understand that each patient's medical condition and overall health may influence their suitability for specific treatments. Lurbinectedin is a novel anticancer drug recently approved by the US Food and Drug Administration (FDA) for the treatment of metastatic small cell lung cancer (SCLC) in adults [1].
As with any medication, lurbinectedin may cause side effects, which could be more severe in certain patient populations. Common side effects include fatigue, decreased neutrophil count, decreased white blood cell count, decreased hemoglobin, increased ALT levels, increased AST levels, decreased appetite, constipation, decreased platelet count, vomiting, and diarrhea [1].
Patients with pre-existing conditions, such as liver or kidney dysfunction, may require closer monitoring during lurbinectedin treatment due to the potential for increased toxicity [1]. In addition, patients with a history of severe hypersensitivity reactions to other drugs may be at a higher risk of experiencing similar reactions to lurbinectedin [1].
It is crucial to consult a healthcare professional for personalized medical advice and to determine whether lurbinectedin is an appropriate treatment option. Healthcare providers will consider the patient's overall health, medical history, and potential drug interactions when making treatment recommendations [1].
In summary, there is no specific patient population that should avoid lurbinectedin based on the available information. However, specific patient populations may require closer monitoring during treatment due to potential increased risks of side effects. Always consult a healthcare professional for personalized medical advice.
Sources:
[1] Lurbinectedin (Zepzelca) [Prescribing Information]. Jazz Pharmaceuticals, Inc.; 2021. Accessed: 2022-08-12. <
https://www.jazzpharma.com/wp-content/uploads/2021/03/Zepzelca-PI-US-2021-03-22.pdf>